Ranibizumab

(Lucentis®)

Lucentis®

Drug updated on 11/16/2023

Dosage FormInjection (intravitreal; 10 mg/ml (0.5 mg), 6mg/ml (0.3 mg))
Drug ClassVascular endothelial growth factor (VEGF) inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For treatment of neovascular (wet) age-related macular degeneration (AMD).
  • For treatment of macular edema following retinal vein occlusion (RVO).
  • For treatment of diabetic macular edema (DME).
  • For treatment of diabetic retinopathy (DR).
  • For treatment of myopic choroidal neovascularization (mCNV).

Product Monograph / Prescribing Information

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of brolucizumab, aflibercept, and ranibizumab for the treatment of patients with visual impairment due to diabetic macular oedema: a systematic review and network meta-analysis.2023Diabetes Therapy
Effect of ranibizumab on retinopathy of prematurity: a meta-analysis.2022Frontiers in Pharmacology
The 12- and 24-month effects of intravitreal ranibizumab, aflibercept, and bevacizumab on intraocular pressure a network meta-analysis.2021Opthalmology
Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials.2021BMJ
A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion.2020Medicine
Intravitreal ranibizumab versus dexamethasone implant in macular edema due to branch retinal vein occlusion: systematic review and meta-analysis.2020European Journal of Ophthalmology
Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies.2020Journal of Clinical Medicine
Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison.2020Advances in Therapy
Comparison of intravitreal bevacizumab and ranibizumab used for myopic choroidal neovascularization: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials.2019Medicine
Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials.2019Drug, Design, Development and Therapy
Assessment report: Lucentis.2019EMA
Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.2018Expert Review of Clinical Pharmacology
Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: a systematic review and meta-analysis.2018Photodiagnosis and Photodynamic Therapy

Clinical Practice Guidelines